Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
23 mai 2024 17h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
23 mai 2024 17h00 HE
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
22 mai 2024 11h20 HE
|
Kymera Therapeutics, Inc.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting ...
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 mai 2024 06h00 HE
|
Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14 mai 2024 10h00 HE
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
09 mai 2024 16h42 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
08 mai 2024 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
07 mai 2024 07h00 HE
|
Arvinas Inc.
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...
Arvinas to Present at Upcoming Investor Conferences
02 mai 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
02 mai 2024 07h00 HE
|
Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...